Overview

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of gilteritinib in male and female participants with severe, mild and moderate renal impairment compared to healthy male and female participants with normal renal function. This study will also evaluate the safety and tolerability of a single oral dose of gilteritinib in male and female participants with severe, mild and moderate renal impairment and healthy male and female participants with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.